Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).

3548Background: Anti-EGFR therapy improves survival for patients (pts) with RAS WT mCRC, but nearly all pts develop therapeutic resistance. MET amplification (amp) is a well-described driver of acq...